What You Should Know About This Hep C Pipeline Drug

By Meaghan Lee CallaghanA new investigational drug for the treatment of hepatitis C could one day give clinicians an option that has fewer drug–drug interactions and only an eight-week treatment duration.Janet Hammond, MD, PhD, the chief development officer at Atea Pharmaceuticals, in Boston, sat down with Infectious Disease Special Edition to talk about their new drug in development, a combination of bemnifosbuvir and ruzasvir. Recent research presented at EASL 2026 (poster FRI-635)